tiprankstipranks
Xencor Highlights Progress in Drug Development Pipeline
Company Announcements

Xencor Highlights Progress in Drug Development Pipeline

Story Highlights
  • Xencor is advancing its XmAb technology for oncology and autoimmune therapies.
  • The company reported significant progress in its clinical programs, including XmAb541 and vudalimab studies.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Stay Ahead of the Market:

An announcement from Xencor ( (XNCR) ) is now available.

Xencor announced updates on its drug development pipeline, highlighting significant progress in several clinical and preclinical programs as of December 31, 2024. Key developments include new data on XmAb541’s selectivity for CLDN6, deep peripheral B-cell depletion observed with plamotamab in lymphoma patients, and resumed dose escalation for XmAb808. Additionally, the company has completed enrollment in three ongoing studies of vudalimab, marking important milestones towards advancing its portfolio of XmAb drug candidates. These advancements reinforce Xencor’s strategic focus on optimizing its antibody platforms to enhance patient outcomes and broaden its market presence in the biopharmaceutical industry.

More about Xencor

Xencor is a biotechnology company that focuses on the development of engineered antibody therapies, particularly in the oncology and autoimmune disease sectors. The company leverages its XmAb technology platforms to create bispecific T-cell engagers and other innovative antibody formats, which are designed to address complex biological challenges and improve therapeutic outcomes.

YTD Price Performance: -13.39%

Average Trading Volume: 617,303

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.44B

See more insights into XNCR stock on TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App